HIV-1 cellular and tissue replication patterns in infected humanized mice

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Araínga, Mariluz ^a   Su, Hang ^a   Poluektova, Larisa Y ^a   Gorantla, Santhi ^a   Gendelman, Howard E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN;

ANIMAL; BONE MARROW; BRAIN; CD4+ T LYMPHOCYTE; DENDRITIC CELL; DISEASE MODEL; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY; LIVER; LUNG; MACROPHAGE; METABOLISM; MONOCYTE; MOUSE; NONOBESE DIABETIC MOUSE; PATHOGENICITY; PHYSIOLOGY; SCID MOUSE; SPLEEN; VIROLOGY; VIRUS REPLICATION;

ANIMALS; ANTIGENS, CD34; BONE MARROW; BRAIN; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV-1; HUMANS; KIDNEY; LIVER; LUNG; MACROPHAGES; MICE; MICE, INBRED NOD; MICE, SCID; MONOCYTES; SPLEEN; VIRUS REPLICATION;

EID: 84961761219     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23513     Document Type: Article

References (60)

1. Ruelas, D. S. & Greene, W. C. An integrated overview of HIV-1 latency. Cell 155, 519-529, doi: 10.1016/j.cell.2013.09.044 (2013).
2. Hill, A. L., Rosenbloom, D. I., Fu, F., Nowak, M. A. & Siliciano, R. F. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci USA 111, 13475-13480, doi: 10.1073/pnas.1406663111 (2014).
3. Baxter, A. E. et al. Macrophage infection via selective capture of HIV-1-infected CD4+ T cells. Cell Host Microbe 16, 711-721, doi: 10.1016/j.chom.2014.10.010 (2014).
4. Sagar, M. Origin of the transmitted virus in HIV infection: infected cells versus cell-free virus. J Infect Dis 210 Suppl 3, S667-673, doi: 10.1093/infdis/jiu369 (2014).
5. Chavez, L., Calvanese, V. & Verdin, E. HIV Latency Is Established Directly and Early in Both Resting and Activated Primary CD4 T Cells. Plos Pathog 11, e1004955, doi: 10.1371/journal.ppat.1004955 (2015).
6. Maldarelli, F. et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179-183, doi: 10.1126/science.1254194 (2014).
7. Margolis, D. M. Confronting proviral HIV infection. Curr HIV/AIDS Rep 4, 60-64 (2007).
8. Sebastian, N. T. & Collins, K. L. Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions. Expert Rev Anti Infect Ther 12, 1187-1201, doi: 10.1586/14787210.2014.956094 (2014).
9. Nixon, C. C. et al. HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice. Blood 122, 2195-2204, doi: 10.1182/blood-2013-04-496950 (2013).
10. Kumar, N. A. et al. The role of antigen presenting cells in the induction of HIV-1 latency in resting CD4(+) T-cells. Retrovirology 12, 76, doi: 10.1186/s12977-015-0204-2 (2015).
11. Laird, G. M. et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 125, 1901-1912, doi: 10.1172/JCI80142 (2015).
12. Rouzine, I. M., Weinberger, A. D. & Weinberger, L. S. An evolutionary role for HIV latency in enhancing viral transmission. Cell 160, 1002-1012, doi: 10.1016/j.cell.2015.02.017 (2015).
13. North, T. W. et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 84, 2913-2922, doi: 10.1128/JVI.02356-09 (2010).
14. Rothenberger, M. K. et al. Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proc Natl Acad Sci USA 112, E1126-1134, doi: 10.1073/pnas.1414926112 (2015).
15. Dash, P. K. et al. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS 26, 2135-2144, doi: 10.1097/QAD.0b013e328357f5ad (2012).
16. Chun, T. W. et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 24, 2803-2808, doi: 10.1097/QAD.0b013e328340a239 (2010).
17. Mavigner, M. et al. Persistence of virus reservoirs in ART-treated SHIV-infected rhesus macaques after autologous hematopoietic stem cell transplant. Plos Pathog 10, e1004406, doi: 10.1371/journal.ppat.1004406 (2014).
18. Mellberg, T. et al. Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV. AIDS Res Ther 8, 21, doi: 10.1186/1742-6405-8-21 (2011).
19. Trono, D. et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 329, 174-180, doi: 10.1126/science.1191047 (2010).
20. Gorantla, S. et al. CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice. J Immunol 184, 7082-7091, doi: 10.4049/jimmunol.1000438 (2010).
21. Gorantla, S., Gendelman, H. E. & Poluektova, L. Y. Can humanized mice reflect the complex pathobiology of HIV-associated neurocognitive disorders? J Neuroimmune Pharmacol 7, 352-362, doi: 10.1007/s11481-011-9335-y (2012).
22. Gorantla, S. et al. Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis. Am J Pathol 177, 2938-2949, doi: 10.2353/ajpath.2010.100536 (2010).
23. Hatziioannou, T. & Evans, D. T. Animal models for HIV/AIDS research. Nat Rev Microbiol 10, 852-867, doi: 10.1038/nrmicro2911 (2012).
24. Li, Q. et al. Early Initiation of Antiretroviral Therapy Can Functionally Control Productive HIV-1 Infection in Humanized-BLT Mice. J Acquir Immune Defic Syndr 69, 519-527, doi: 10.1097/QAI.0000000000000687 (2015).
25. Yamada, E. et al. Impacts of humanized mouse models on the investigation of HIV-1 infection: illuminating the roles of viral accessory proteins in vivo. Viruses 7, 1373-1390, doi: 10.3390/v7031373 (2015).
26. Halper-Stromberg, A. et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158, 989-999, doi: 10.1016/j.cell.2014.07.043 (2014).
27. Marsden, M. D. et al. HIV latency in the humanized BLT mouse. J Virol 86, 339-347, doi: 10.1128/JVI.06366-11 (2012).
28. Tager, A. M., Pensiero, M. & Allen, T. M. Recent advances in humanized mice: accelerating the development of an HIV vaccine. J Infect Dis 208 Suppl 2, S121-124, doi: 10.1093/infdis/jit451 (2013).
29. Berges, B. K., Wheat, W. H., Palmer, B. E., Connick, E. & Akkina, R. HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/- gamma c-/- (RAG-hu) mouse model. Retrovirology 3, 76, doi: 10.1186/1742-4690-3-76 (2006).
30. Salgado, M. et al. HLA-B∗57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice. J Virol 88, 3340-3352, doi: 10.1128/JVI.03380-13 (2014).
31. Pinkevych, M. et al. HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission. Plos Pathog 11, e1005000, doi: 10.1371/journal.ppat.1005000 (2015).
32. Whitney, J. B. et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512, 74-77, doi: 10.1038/nature13594 (2014).
33. Denton, P. W. et al. Generation of HIV latency in humanized BLT mice. J Virol 86, 630-634, doi: 10.1128/JVI.06120-11 (2012).
34. Marsden, M. D. & Zack, J. A. Studies of retroviral infection in humanized mice. Virology 479-480, 297-309, doi: 10.1016/j. virol.2015.01.017 (2015).
35. Bernard-Stoecklin, S., Gommet, C., Cavarelli, M. & Le Grand, R. Nonhuman primate models for cell-associated simian immunodeficiency virus transmission: the need to better understand the complexity of HIV mucosal transmission. J Infect Dis 210 Suppl 3, S660-666, doi: 10.1093/infdis/jiu536 (2014).
36. Eriksson, S. et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. Plos Pathog 9, e1003174, doi: 10.1371/journal.ppat.1003174 (2013).
37. Estes, J. D. Pathobiology of HIV/SIV-associated changes in secondary lymphoid tissues. Immunol Rev 254, 65-77, doi: 10.1111/imr.12070 (2013).
38. Josefsson, L. et al. Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4+ T-cells contain one HIV-1 DNA molecule. Plos Pathog 9, e1003432, doi: 10.1371/journal.ppat.1003432 (2013).
39. Choudhary, S. K. et al. Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/- {gamma}c-/- mouse. J Virol 83, 8254-8258, doi: 10.1128/JVI.00580-09 (2009).
40. Metcalf Pate, K. A. et al. A Murine Viral Outgrowth Assay to Detect Residual HIV Type 1 in Patients With Undetectable Viral Loads. J Infect Dis, doi: 10.1093/infdis/jiv230 (2015).
41. Buzon, M. J. et al. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol 88, 10056-10065, doi: 10.1128/JVI.01046-14 (2014).
42. Buzon, M. J. et al. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat Med 20, 139-142, doi: 10.1038/nm.3445 (2014).
43. O'Connell, K. A., Rabi, S. A., Siliciano, R. F. & Blankson, J. N. CD4+ T cells from elite suppressors are more susceptible to HIV-1 but produce fewer virions than cells from chronic progressors. Proc Natl Acad Sci USA 108, E689-698, doi: 10.1073/pnas.1108866108 (2011).
44. Okulicz, J. F. et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 200, 1714-1723, doi: 10.1086/646609 (2009).
45. Rabi, S. A. et al. Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection. J Virol 85, 979-986, doi: 10.1128/JVI.01721-10 (2011).
46. Yang, Y. et al. CD4 T-cell regeneration in HIV-1 elite controllers. AIDS 26, 701-706, doi: 10.1097/QAD.0b013e3283519b22 (2012).
47. Kim, M. et al. A primary CD4(+) T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence. Nat Protoc 9, 2755-2770, doi: 10.1038/nprot.2014.188 (2014).
48. Perez, R. et al. Distribution of HIV-1 infection in different T lymphocyte subsets: antiretroviral therapy-naive vs. experienced patients. AIDS Res Hum Retroviruses 27, 399-410, doi: 10.1089/aid.2010.0176 (2011).
49. Politch, J. A., Marathe, J. & Anderson, D. J. Characteristics and quantities of HIV host cells in human genital tract secretions. J Infect Dis 210 Suppl 3, S609-615, doi: 10.1093/infdis/jiu390 (2014).
50. Fischer-Smith, T., Bell, C., Croul, S., Lewis, M. & Rappaport, J. Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies. J Neurovirol 14, 318-326, doi: 10.1080/13550280802132857 (2008).
51. Kadiu, I. & Gendelman, H. E. Macrophage bridging conduit trafficking of HIV-1 through the endoplasmic reticulum and Golgi network. J Proteome Res 10, 3225-3238, doi: 10.1021/pr200262q (2011).
52. Kenway-Lynch, C. S., Das, A., Lackner, A. A. & Pahar, B. Cytokine/Chemokine responses in activated CD4+ and CD8+ T cells isolated from peripheral blood, bone marrow, and axillary lymph nodes during acute simian immunodeficiency virus infection. J Virol 88, 9442-9457, doi: 10.1128/JVI.00774-14 (2014).
53. Walker, B. D. & Yu, X. G. Unravelling the mechanisms of durable control of HIV-1. Nat Rev Immunol 13, 487-498, doi: 10.1038/nri3478 (2013).
54. Archin, N. M. et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci USA 109, 9523-9528, doi: 10.1073/pnas.1120248109 (2012).
55. Strain, M. C. et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 191, 1410-1418, doi: 10.1086/428777 (2005).
56. Farber, D. L., Yudanin, N. A. & Restifo, N. P. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol 14, 24-35, doi: 10.1038/nri3567 (2014).
57. Epstein, A. A. et al. Combinatorial assessments of brain tissue metabolomics and histopathology in rodent models of human immunodeficiency virus infection. J Neuroimmune Pharmacol 8, 1224-1238, doi: 10.1007/s11481-013-9461-9 (2013).
58. Gendelman, H. E. et al. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med 167, 1428-1441 (1988).
59. Pasternak, A. O. et al. Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol 46, 2206-2211, doi: 10.1128/JCM.00055-08 (2008).
60. Agosto, L. M. et al. HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology 368, 60-72, doi: 10.1016/j.virol.2007.06.001 (2007).